Authors

• Shun Takao
• Naoko Matsumoto (ORCID: https://orcid.org/0000-0003-0506-1163)
• Noboru Hattori (ORCID: https://orcid.org/0000-0002-8234-942X)
• Yuko Toyoda (ORCID: https://orcid.org/0000-0002-9124-7978)
• Chihiro Ando (ORCID: https://orcid.org/0000-0003-3775-7536)
• Kakuhiro Yamaguchi (ORCID: https://orcid.org/0000-0002-9117-1934)
• Nobuhiro Kanaji (ORCID: https://orcid.org/0000-0001-7365-4927)
• Hiroshi Iwamoto (ORCID: https://orcid.org/0000-0003-4922-5334)
• Yasunari Nagasaki
• Masaaki Yanai
• Tamio Okimoto (ORCID: https://orcid.org/0000-0001-8295-1296)
• Tetsu Hirakawa
• Hisao Higo (ORCID: https://orcid.org/0000-0003-4946-0123)
• Sachie Ono (ORCID: https://orcid.org/0000-0002-4233-6675)
• Koji Kurose
• Kosuke Oyama (ORCID: https://orcid.org/0009-0004-7821-5236)
• Masako Watanabe
• S Tada
• Kozue Miyazaki

Institutions

• Hiroshima University (JP)
• Shimane University (JP)
• Kawasaki Medical School (JP)
• Kagawa University (JP)
• Okayama University Hospital (JP)
• Hiroshima City Asa Citizens Hospital (JP)
• Hiroshima Red Cross Hospital & Atomic-bomb Survivors Hospital (JP)
• Okayama Red Cross General Hospital (JP)
• Yamaguchi University Hospital (JP)
• Japanese Red Cross Kochi Hospital (JP)
• Tottori University Hospital (JP)
• Higashihiroshima Medical Center (JP)
• National Hospital Organization (JP)
• Science and Technology Corporation (United States) (US)
• Kōchi University (JP)

Publication Details

Journal

European Journal of Cancer

Published

2025-07-05

DOI

https://doi.org/10.1016/j.ejca.2025.115606

Primary Topic

Cancer Immunotherapy and Biomarkers

Type

article

Field-Weighted Citation Impact

0.00

Funders

• Japan Agency for Medical Research and Development